Based on sound preclinical evidence for increased sensitivity of BRCA1-deficient breast cancer cells to platinating agents, this Polish-Canadian research team has taken a risk of recruiting potentially operable and yet chemonaive breast cancer patients for the study. Here, BRCA1 is linked to breast carcinoma.